MGMT and glioblastoma: Indeed, it has been reported that GBM patients with MGMT promoter methylation respond better than unmethylated patients for the concomitant TMZ and radiotherapy, making MGMT methylation a critical biomarker for predicting sensitivity to TMZ therapy.